References
- Petrich AM, Rosen ST. Peripheral T-cell lymphoma: new therapeutic strategies. Oncology 2013;27:878–884.
- Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467–1475.
- Smith SM, Burns LJ, van Besien K, et al. Hematopoietic stem cell transplantation for systemic mature peripheral T-cell lymphoma. J Clin Oncol 2013;31:3100–3109.
- Agostinelli C, Piccaluga P, Went P, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol 2008;61:1160–1167.
- Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and potential new therapeutic targets. J Clin Invest 2007;117:823–834.
- Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous administration. J Clin Pharmacol 2004;44:158–162.
- Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
- Laimer D, Dolznig H, Kollmann K, et al. PDGFR blockade is a rationale and effective therapy for NPM-ALK-driven lymphomas. Nat Med 2012;18:1699–1704.
- Ruan J, Luo M, Wang C, et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 2013;121:5192–5202.
- William BM, Hohenstein M, Loberiza FR, et al. Phase I/II study of dasatinib in relapsed/refractory non-Hodgkin lymphoma (NHL). Blood 2010;116(Suppl. 1): Abstract 288.
- Brauns TC, Schultewolter T, Dissemond J, et al. C-KIT expression in primary cutaneous T cell lymphomas. J Cutan Pathol 2004;31: 577–582.
- Choe YS, Kim JG, Sohn SK, et al. c-kit Expression and mutations in peripheral T-cell lymphomas except for extra-nodal NK/T cell lymphomas. Leuk Lymphoma 2006;47:267–270.
- Yang Y, Liu C, Peng W, et al. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT murine mastocytoma and are potentiated by anti-OX40. Blood 2012;120:4533–4543.